Q3 2025 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2025-11-13 · accession 0001104659-25-111321
$752.6M
Reported value
9
Positions
2025-09-30
Period end
The Brief · Atlas Venture Life Science Advisors, LLC · Q3 2025
AI · grounded in 13F
Atlas Venture Life Science Advisors, LLC established a new position in Kymera Therapeutics, Inc. KYMR valued at $277.1M. The fund also initiated new stakes in Disc Medicine, Inc. IRON for $141.6M and Dyne Therapeutics, Inc. DYN for $115.5M. Additional new positions include Sionna Therapeutics, Inc. SION, Korro Bio, Inc. KRRO, and Day One Biopharmaceuticals, Inc. DAWNGBX.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $277.1M | 36.8% | 4,896,462 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $141.6M | 18.8% | 2,142,617 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $115.5M | 15.3% | 9,130,465 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $106.3M | 14.1% | 3,615,527 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $54.5M | 7.24% | 1,137,149 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $45.3M | 6.02% | 6,430,257 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $5.1M | 0.67% | 827,946 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $4.1M | 0.55% | 2,092,106 | Common | SOLE |
| 45175G207 | IMA | ImageneBio, Inc. | $3.1M | 0.41% | 377,814 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.